57 results about "Ferritin receptors" patented technology

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by, providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.

The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin / transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and / or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety. Other uses for TfR specific VNAR binding moieties of the invention include, e.g., regulating the interaction of iron-charged transferrin with TfR (receptor cycling or cell surface presentation), such as may be therapeutic in treatment of certain cancer cells and tumors of various tissue types.

Enrichment for human Keratinocyte Stem Cells KSCs to a high degree of purity can be successfully achieved on the basis of a cell surface component whose expression is proliferation-related in conjunction with an integrin such as the alpha6beta4 integrin. Transferrin receptor may be used as the cell surface component that is proliferation related. Enrichment of Transit amplifying cells can also be achieved by use of a variation of this method. The enrichment follows on from harvesting of cells from an epithelium, preferably rich in stem cells.

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.

The invention discloses a liposome preparation containing antineoplastic metallic complex which is derived by hydrophilic polymers and aglycones, in one embodiment, the antineoplastic metallic complex includes Oxaliplatin, the hydrophilic polymers include polyethylene glycol, the aglycone is transferrin. In accordance with the invention, the transferring expressed on the surface of the tumor cell can facilitate the absorption of agent in the liposome by the tumor cells. The invention also provides the pharmaceutical composition containing the liposome and method for application.

The invention discloses a nucleic acid aptamer sequence for recognizing and being combined with a human transferrin receptor and application of the nucleic acid aptamer sequence. A nucleic acid aptamer and derivatives thereof can be applied in kits, molecular probes and targeted media for recognizing or preparing and detecting transferrin receptor high-expression tumors and applied in nucleic acid probes for designing, preparing and detecting transferrin receptors. The nucleic acid aptamer has the advantages that the affinity and specificity are higher than those of the prior art, the aptamer is free of immunogenicity, chemical synthesis can be achieved, and the nucleic acid aptamer is small in molecular weight, stable, easy to store and mark and the like.

The present invention discloses modified fusion proteins of transferrin and therapeutic proteins or peptides, which have prolonged serum half-life or increased serum stability. Preferred fusion proteins include those modified such that the transferrin component exhibits no or reduced glycosylation, binding to iron, and / or binding to the transferrin receptor.

The invention discloses a docetaxel transferrin acceptor-targeted liposome preparation. The preparation is prepared with a preparation method comprising the following steps of: mixing 55-95 parts by weight of phospholipid, 3-40 parts by weight of cholesterol and 0.05-20 parts by weight of docetaxel; dissolving into ethanol; performing rotary evaporation; adding 0.5-1.5ml of a phosphate buffer solution, and hydrating to obtain a liposome; and connecting a transferrin ligand to a liposome surface which contains docetaxel by applying a backward embedding technology to obtain a docetaxel transferrin acceptor-targeted liposome preparation, wherein the average particle diameter of the preparation is 60-100 nanometers, and the interfacial potential is -10mV to 20mV. As proved by a cytotoxicity research result, compared with a non-targeted liposome, a transferrin acceptor-targeted liposome has the advantage that: the toxicity of docetaxel on KB cells can be enhanced remarkably. The docetaxel transferrin acceptor-targeted liposome disclosed by the invention can become a novel medicament preparation for treatment cancers in future.

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and / or binding to the transferrin receptor.

The invention discloses a method for preparing a fluorescent probe with a tumor targeting effect by taking ferritin as a carrier. The ferritin carrier comprises human heavy chain ferritin. The methodcomprises the following steps: depolymerizing the human heavy chain ferritin with a cage-shaped structure into a monomer state; adding coumarin-6 with fluorescent properties into the depolymerized human heavy chain ferritin and combining the coumarin-6 with the ferritin; and re-polymerizing the depolymerized human heavy chain ferritin combined with the coumarin-6 into nanoparticles. The nano probeprepared by the invention has good biocompatibility and can be specifically enriched on the surface of tumor cells of an overexpression transferrin receptor 1(TfR1); and an efficient detection methodis provided for in-vivo tracing of a drug delivery system by utilizing the fluorescent property of the coumarin-6.

The present invention relates to a transferrin receptor content detection kit, which comprises a reagent I and a reagent II, wherein the components of the reagent I comprise a buffer, a preservative, a chelating agent, a surfactant and water, the components of the reagent II comprise anti-transferrin receptor antibody coated latex microsphere particles, a buffer, a preservative, an auxiliary suspending agent and water, and the particle size of the anti-transferrin receptor antibody coated latex particles is 120-200 nm. The invention further relates to a preparation method for the transferrin receptor content detection kit, wherein the anti-transferrin receptor antibody coated latex microsphere particles are prepared by using a chemical cross-linking method. According to the present invention, the amino group latex microsphere particles with the appropriate particle size are selected and the chemical cross-linking method is adopted to prepare the latex microsphere particles, such that the sensitivity and the stability of the prepared transferrin receptor detection kit are increased, and the shelf life and the bottle opening stable phase are prolonged.

H-ferritin receptors on endothelial cells In rat brain rat brain microvasculature are a means for transporting iron across the blood brain barper. A method for treating an iron deficiency disorder in the brain of a patient comprises administepng to a patient in need an H- ferritin-iron complex. A method for using H-ferritin as a targeting moiety comprises attaching H-ferritin to a liposome targeted to the brain or cells within the brain. A method for treating an iron overload disorder in a patient comprises administering to a patient a multi subunit ferritin complex at less than 100% iron binding capacity.

An isolated and purified non-denatured transferrin receptor protein of a Moraxella strain, particularly M. catarrhalis, has an apparent molecular mass of about 80 to about 90 kDa, as determined by SDS-PAGE. The transferrin receptor protein or a fragment analog thereof is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a strain of Moraxella. The transferrin receptor protein is isolated from strains of Moraxella catarrhalis by a procedure including extraction of agent soluble proteins of a cell mass produced by cultivating the strain under iron-starved conditions. The transferrin receptor protein is selectively solubilized from the extracted cell mass and purified.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

A transferring-polyethanediol-medicine molecule composition for the target therapy of tumor is disclosed. It features the combination of transferring and polyethanediol to make it has both active and passive target functions. Its advantages are long semi-life and high accumulation degree in tumor tissue. It can be used to prepare the antineoplastic medicines.

The invention discloses an active peptide capable of being specifically combined with TfR1. The active peptide has an amino acid sequence as shown in SEQ ID NO:1. The in-vitro experiment shows that the active peptide can be combined with cells capable of high-expressing transferrin receptors, and coupled fluorescein isothiocyanate (FITC) can be transferred into cells specifically. Therefore, the combined peptide disclosed by the invention can be applied to a medicine targeted carrier which takes the transferrin receptors as target points, and has significant meanings for development of tumor target medicines, target treatment on brain-derived diseases, prediction on the transferrin receptors as targets, and tumor happening and development diagnosis.

Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

The invention provides a contrast agent capable of specifically imaging tumor and neurodegenerative diseases (including Alzheimer's disease (AD), Parkinson's disease (PD) and the like) in magnetic resonance imaging and a preparation method thereof by using the high affinity between lactoferrin and cells which express a lactoferrin receptor on surface to realize target-directed imaging. The magnetic resonance contrast agent is formed by conjugating super-paramagnetic ferric oxide nanoparticles with lactoferrin, the particle size of the magnetic resonance contrast agent is below 20 nanometers, and the conjugate has the characteristics of small particle size, no toxicity, high specificity, high selectivity, high contrast effect, tissue concentration enough for in-vivo imaging, and the like.

The invention discloses a transferrin-frogspawn ribalgilase conjugate which belongs to the biological medicine field. The conjugate includes one transferrin and 1-5 frogspawn ribalgilase. The invention also discloses a method for preparing the conjugate, an use and a pharmaceutical composition containing the conjugate. Many tumour cells high express transferrin receptor, and transferrin is easy to be endocytosis after combining with the receptor, accordingly the conjugate is easy to enter into cytolymph than dissociative frogspawn ribalgilase and has stronger and special ability for killing tumour cell.

The invention belongs to the technical field of fish molecular mark screening and application and particularly relates to a megalobrama amblycephala transferrin receptor gene SNP molecule mark and applications thereof. The molecule mark can be used for assisting megalobrama amblycephala disease-resistant variety selection. The molecule mark is prepared by cloning from a transferrin receptor gene that is GenBnk accession No.KM225267. The nucleotide sequence of the molecular mark is shown as SEQ ID NO:1. The R at the number 267 base site of the sequence is A or G (with the mutant being in a gene intron portion). The mutant leads to NocI enzyme digestion polymorphism. Application of utilizing the screened molecular mark to perform correlation analysis on megalobrama amblycephala disease-resistant characters proves that the molecular mark can be used for assisting megalobrama amblycephala disease-resistant character selection.

The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Provided is a biomarker for detecting colorectal cancer at an earlier stage. A colorectal cancer biomarker for detecting colorectal cancer includes at least one protein selected from 22 proteins, i.e., proteins 1 to 22, or at least one peptide selected from partial peptides of proteins 1 to 22: 1) annexin A11; 2) annexin A3; 3) annexin A4; 4) tenascin-N; 5) transferrin receptor protein 1; 6) glucose transporter 1; 7) complement component C9; 8) CD88 antigen; 9) 78-kDa glucose-regulated protein; 10) alpha-1-acid glycoprotein; 11) matrix metalloprotease 9; 12) angiopoietin-1; 13) CD67 antigen; 14) mucin-5B; 15) adapter protein GRB2; 16) annexin A5; 17) olfactomedin-4; 18) neutral amino acid transporter B(0); 19) tripeptidyl peptidase 1; 20) heat shock-related 70-kDa protein 2; 21) proteasomesubunit alpha type-5; and 22) neutrophil gelatinase-associated lipocalin.